Search Results
Your search for The ASCO Post Staff ,The ASCO Post Staff matches 6182 pages
Showing 4551 - 4600ASCO Position Statement Recommends Specific Actions for Applying Telemedicine in Cancer Care During Pandemic and Beyond
A new position statement by ASCO calls for the continuation of flexibilities in reimbursement that have allowed the expanded use of telemedicine during the COVID-19 pandemic. The statement, which also calls for further research on telemedicine’s effectiveness and benefits, offers recommendations...
New Chief of Oncologic Quality at Rutgers/Robert Wood Johnson
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, have welcomed Henry A. Pitt, MD, to its team of physicians, researchers, and administrators. Dr. Pitt is the new Chief of Oncologic Quality, a role that provides leadership and...
Theodore Laetsch, MD, Joins Children’s Hospital of Philadelphia to Launch Very Rare Malignant Tumors Program
Pediatric hematologist-oncologist Theodore Laetsch, MD, has joined the Division of Oncology at Children’s Hospital ofPhiladelphia (CHOP), where he will launch a cutting-edge Very Rare Malignant Tumors Program that will seek to develop new treatments for children with rare and complex tumors. In...
Cervical Cancer Screening and Prevention in Low- and Middle-Income Countries: 2020
Cervical cancer is a worldwide public health problem. The incidence of the disease is particularly high in low- and middle-income countries, where low coverage of prevention strategies and high risk of infection persist. To reduce morbidity and mortality, improved screening and prevention are...
Seattle Cancer Care Alliance Expands South Lake Union Campus
Seattle Cancer Care Alliance (SCCA) announced the beginning of construction on its South Lake Union campus to add a six-story, 150,000 square-foot outpatient cancer treatment clinic. The largest single construction project in SCCA history, the new building will feature a patient-centered design,...
Dana-Farber Launches New Center for Prevention and Treatment of BRCA-Related Cancers
Of the tens of thousands of genes in cellular DNA, one group of genes is tasked with ensuring that every cell reproduces itself exactly when it divides to make new cells. Perhaps the best known of these genes are the BRCA genes, which if inherited with a significant alteration, confer a markedly...
Three Scientists at Johns Hopkins Tapped to Join Exclusive Research Network
Among the first 45 members selected to join the 10x Genomics Visium Clinical Translational Research Network are 3 scientists from Johns Hopkins Kimmel Cancer Center. The organization is aimed at advancing translational research in some of the world’s leading health problems, including oncology,...
LUNGevity, FDA Launch Lung Cancer Patient Research Project
LUNGevity Foundation, a nonprofit organization focused on lung cancer, recently announced the launch of a new longitudinal study in collaboration with the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence. The project, understanding the lung cancer patient experience in the...
Setting an Ambitious Path to Ensure Health Equity for All Patients With Cancer
In keeping with her Presidential theme of “Equity: Every Patient, Every Day, Everywhere,” in July, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, announced the Society was joining forces with the Association of Community Cancer Centers (ACCC) to increase racial and ethnic minority participation...
Large Study Finds No Link Between Antihypertensives and Cancer
There appears to be no evidence that blood pressure–lowering drugs increase the risk of cancer, according to the most extensive study conducted on the topic, which was presented at the European Society of Cardiology Congress 2020.1 “Our results should reassure the public about the safety of...
CDC Data Show Disproportionate COVID-19 Impact in American Indian and Alaska Native Populations
The Centers for Disease Control and Prevention (CDC) released a new study that specifically examines how COVID-19 is affecting American Indians and Alaska Natives (AI/AN), one of the racial and ethnic minority groups at highest risk from the disease. The CDC found that in 23 selected states, the...
Leaders in Radiation Oncology Awarded ASTRO Fellow Designation
The American Society for Radiation Oncology (ASTRO) has selected 19 distinguished members to receive the ASTRO Fellow (FASTRO) designation. The 2020 class of Fellows will be recognized at a virtual awards ceremony on October 27 during ASTRO’s 62nd Annual Meeting. The ASTRO Fellows program...
Fox Chase Cancer Center Welcomes Robert Brenchak, MD
Fox Chase Cancer Center recently announced the hiring of Robert Brenchak, MD, who will join the Department of Medicine as Assistant Professor in the Division of Hospital Medicine. Dr. Brenchak is coming to Fox Chase from Temple University Hospital, where he was Assistant Professor of Clinical...
Moffitt Cancer Center Names Patrick Hwu, MD, as President and Chief Executive Officer
Tumor immunologist Patrick Hwu, MD, has been appointed the new President and Chief Executive Officer (CEO) of Moffitt Cancer Center. He joins Moffitt from The University of Texas MD Anderson Cancer Center, where he is Division Head of Cancer Medicine. Dr. Hwu begins his new role at Moffitt on...
Tracy Onega, PhD, Named Senior Director of Population Sciences at Huntsman Cancer Institute
Tracy Onega, PhD, has been appointed Senior Director of Population Sciences at Huntsman Cancer Institute (HCI) and Professor of Population Sciences at the University of Utah. A cancer epidemiologist, Dr. Onega conducts research focused on cancer control, including health information technology,...
Messino Cancer Centers Founder Michael Messino, MD, Receives North Carolina Governor’s Award
Messino Cancer Centers, a partner practice of American Oncology Network, announced that medical oncologist Michael Messino, MD, has received the highest award granted by North Carolina’s Office of the Governor. The Order of the Long Leaf Pine is presented to individuals who have shown extraordinary ...
Study Indicates Delaying Antiviral Treatment May Boost Immunity in Stem Cell Transplant Recipients
A team of cellular-therapy specialists from Roswell Park Comprehensive Cancer Center has found that patients who develop cytomegalovirus (CMV) infections after allogeneic stem cell transplantation may be able to develop an immunity against the virus, strengthen their immune system, and reduce...
NCI, Cancer Research UK Launch Cancer Grand Challenges Partnership
The National Cancer Institute (NCI), part of the National Institutes of Health, will partner with Cancer Research UK to fund Cancer Grand Challenges, an international initiative to address profound and unanswered questions in cancer research. Through Cancer Grand Challenges, the NCI and Cancer...
American College of Surgeons Launches New Cancer Surgery Standards Program to Improve Quality of Care
The American College of Surgeons Cancer Programs recently launched the Cancer Surgery Standards Program (CSSP), a new initiative that aims to improve the quality of surgical care provided to patients with cancer by implementing standards for cancer surgery and standardizing the way operative data...
Karmanos Receives $630,000 CATCH-UP Grant to Recruit Minority, Rural Patients to Clinical Trials
Researchers at the Barbara Ann Karmanos Cancer Institute have secured a 1-year, $630,000 grant from the National Cancer Institute (NCI) that will help support the Institute’s clinical trials, which target underserved populations in Detroit and in the rural areas that Karmanos serves. The NCI P30...
Implementation of RACE for Children Act Helps Address Unmet Needs of Children With Cancer
The following statement was recently issued by Monica M. Bertagnolli, MD, FACS, FASCO, Chair of the Association for Clinical Oncology, the affiliate organization of the Society: ASCO applauds implementation of the Research to Accelerate Cures and Equity (RACE) for Children Act. Applications to the ...
Research Provides Genetic, Immune-Related Information on Pancreatic Neuroendocrine Tumors
Scientists have used artificial intelligence in an extensive analysis of the immune and genetic landscapes of pancreatic neuroendocrine tumors. Their findings were published by Young et al in the journal Gut. Pancreatic neuroendocrine cancer starts in cells that produce hormones such as insulin....
New Study Focuses on Multiorgan Immunotherapy-Related Adverse Events in Clinical Trials
A new study published by Kichenadasse et al in JNCCN—Journal of the National Comprehensive Cancer Network concentrates on how immunotherapy-related adverse events may impact more than one organ in a single patient. This study provides new information on how frequently multiorgan side effects occur...
FDA Issues Alert About Efficacy and Potential Safety Concerns Regarding Atezolizumab Plus Paclitaxel in Metastatic Triple-Negative Breast Cancer
On September 8, the U.S. Food and Drug Administration (FDA) alerted health-care professionals, oncology clinical investigators, and patients that a clinical trial studying the use of atezolizumab and paclitaxel in patients with previously untreated, inoperable, locally advanced or metastatic...
FDA Approves Pralsetinib for Metastatic RET Fusion–Positive NSCLC
On September 4, the U.S. Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for the treatment of adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test. The approval is based on data from the phase I/II ARROW...
FDA Pipeline: Priority Reviews in Multiple Myeloma, Metastatic Breast Cancer, and NSCLC
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to agents for the treatment of refractory multiple myeloma, metastatic breast cancer, and metastatic non–small cell lung cancer (NSCLC); gave Fast Track designation to treatments for NTRK mutation–positive solid tumors...
Research Shows ‘Social Smoking’ Raises Risk of Death From Lung Disease and Lung Cancer
Low-intensity smokers—individuals who smoke fewer than 10 cigarettes per day—are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than nonsmokers, according to research presented by Balte et al at the European Respiratory Society...
Osimertinib vs Platinum/Pemetrexed and Overall Survival in Patients With EGFR T790M Advanced NSCLC: AURA3 Trial
In patients with epidermal growth factor receptor (EGFR) T790M advanced non–small cell lung cancer (NSCLC), no statistically significant benefit in overall survival was observed with osimertinib vs pemetrexed plus carboplatin/cisplatin (platinum/pemetrexed) treatment, which possibly reflects the...
Expert Point of View: TROPHIMMUN Trial
Two gynecologic oncologists and ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, commented on the findings of the TROPHIMMUN trial for The ASCO Post. “The authors demonstrate efficacy of a new treatment approach for gestational trophoblastic...
TROPHIMMUN Trial Finds Avelumab Effective in Rare Gynecologic Tumor Resistant to Chemotherapy
The first trial of immunotherapy for gestational trophoblastic tumors proved effective in almost 50% of patients resistant to single-agent chemotherapy, French investigators reported in an abstract presented during the ASCO20 Virtual Scientific Program.1 The results of the phase II TROPHIMMUN trial ...
American Cancer Society Updates Guideline for Cervical Cancer Screening
An updated cervical cancer screening guideline from the American Cancer Society has called for less—and more simplified—screening. The guideline was published by Elizabeth T.H. Fontham, MPH, DrPH, of Louisiana State University School of Public Health, New Orleans, and colleagues in CA: A Cancer...
Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer
Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...
Lenvatinib/Pembrolizumab in Previously Treated Patients With Advanced Endometrial Cancer
As reported in the Journal of Clinical Oncology by Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, findings from a phase Ib/II trial indicate that the combination of lenvatinib and pembrolizumab is active in patients with previously treated advanced...
Addition of Trastuzumab to Carboplatin/Paclitaxel for Advanced or Recurrent HER2-Positive Uterine Serous Carcinoma
Combining the HER2-targeted therapy trastuzumab with carboplatin and paclitaxel improved survival rates for women with a rare, aggressive type of endometrial cancer, according to findings published by Amanda N. Fader, MD, of Johns Hopkins School of Medicine, Baltimore, and colleagues in Clinical...
LACC Trial: Quality of Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer
As reported in The Lancet Oncology by Michael Frumovitz, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for...
PORTEC-3: Effect of Molecular Classification of Endometrial Cancer on Outcomes With Adjuvant Therapy
In a study reported in the Journal of Clinical Oncology, Alicia Léon-Castillo, MD, of Leiden University Medical Center, the Netherlands, and colleagues identified outcomes associated with molecular subgroups of patients with high-risk endometrial cancer enrolled in the PORTEC-3 trial of adjuvant...
Gynecologic Oncologist Describes Practice in the Era of COVID-19
The ASCO Post spoke with Alexander Melamed, MD, MPH, a gynecologic oncologist and Assistant Professor of Obstetrics & Gynecology at NewYork-Presbyterian/Columbia University Medical Center, New York, at the onset of the COVID-19 pandemic in New York. New York state has had more coronavirus cases ...
Expert Point of View: Shannon N. Westin, MD, MPH, FACOG
Discussant of the abstract on the WEE1 inhibitor adavosertib, Shannon N. Westin, MD, MPH, FACOG, Associate Professor and clinical investigator at The University of Texas MD Anderson Cancer Center, called the interaction between p53 and WEE1 an “opportunity for synthetic lethality.” She continued:...
SGO 2020: WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma
Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series. The initial ...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
Expert Point of View: Kathleen N. Moore, MD
Kathleen N. Moore, MD, Associate Professor of Gynecologic Oncology and Director of the Oklahoma TSET Phase I Clinical Trials Program, Stephenson Cancer Center, Oklahoma City, underscored the importance of studying patients with stable disease and less robust partial response, not just those with...
ESMO 2019: Immunotherapy in Cervical and Endometrial Cancers
In studies reported at the ESMO Congress 2019, immunotherapy yielded encouraging outcomes in two gynecologic cancer populations in need of new treatments, including patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer....
SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
ASCO20: Cediranib Plus Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however,...
Effect of Statins on Survival in Ovarian Cancer
Lipophilic statin use was associated with reduced mortality in women with epithelial ovarian cancer and all subtypes in a large observational study compared with never users. These findings were presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II. Lead...
KEYNOTE-100: In Women With Advanced Ovarian Cancer, Pembrolizumab Yields Modest Antitumor Efficacy
the final results of the phase II KEYNOTE-100 study of pembrolizumab in women with advanced and recurrent ovarian cancer showed that pembrolizumab monotherapy produced modest clinical activity. Ursula Matulonis, MD, of Dana-Farber Cancer Institute, Harvard Medical School, reported the data at the...
ASCO20: Final Overall Survival Analysis From SOLO2 in Ovarian Cancer
For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...
Expert Point of View: Robert L. Coleman, MD
Discussant of the DESKTOP III and SOC1 trials, Robert L. Coleman, MD, of U.S. Oncology Research in Woodlands, Texas, congratulated the authors of both trials. He put these results in perspective with the GOG-0213 study, which did not show a survival benefit for secondary surgery. “There are general ...
ASCO20: Secondary Surgery May Extend Survival in Recurrent Ovarian Cancer
Two phase III trials provided support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the...
ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Ovarian Cancer
In the phase III VELIA/GOG-3005 trial—reported at the European Society for Medical Oncology (ESMO) Congress 20191 and simultaneously published in The New England Journal of Medicine2—Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the ...
